All patients enrolled will undergo 5 additional (6 total) SPECT/CT scans per treatment cycle. Current FDA approved PSMA radioligand therapy is administered over 6 cycles, so there will be a total of 30 additional SPECT/CT scans during this study.
During each treatment cycle, patients will have a SPECT/CT scan at the following time points after administration of PRLT:
- 4 Hours
- 24 Hours (+/- 8 Hours)
- 48 Hours (+/- 8 Hours)
- 96 Hours (+/- 8 Hours)
- 168 Hours (+/- 24 Hours)
- 336 Hours (+/- 24 Hours)
SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
